Oropharyngeal Cancer

Outcomes Are Better for HPV16-Associated Oropharyngeal Cancer, but Not for Other HPV Strains

Outcomes Are Better for HPV16-Associated Oropharyngeal Cancer, but Not for Other HPV Strains

By

Patients with oropharyngeal tumors that harbor HPV16 have higher 5-year survival and lower recurrence rates than patients with tumors that harbor other HPV strains or are HPV-negative.

Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer

Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer

By

Transoral robotic surgery (TORS) with or without radiation therapy or chemotherapy is an effective treatment option for patients with oropharyngeal cancer regardless of their p16 status.

Poor Oral Health Associated With OPSCC Regardless of HPV Status

Poor Oral Health Associated With OPSCC Regardless of HPV Status

By

Despite a higher risk for HPV-negative orophayngeal squamous cell carcinoma (OPSCC), poor oral health appears to be associated with OPSCC regardless of HPV status.

Incidence of Oropharyngeal Cancer Increasing Among Older Patients

Incidence of Oropharyngeal Cancer Increasing Among Older Patients

By

The incidence of oropharyngeal squamous cell carcinoma is increasing among older patients residing in the United States, likely due to the increase in HPV-associated malignancies.

CDC: Most HPV-Linked Cancers Are Preventable

CDC: Most HPV-Linked Cancers Are Preventable

Cervical cancer, and oropharyngeal cancers in men, account for most HPV-associated cancers.

More Than HPV Vaccine Uptake Is Needed to Reduce the Burden of HPV-associated Cancers

More Than HPV Vaccine Uptake Is Needed to Reduce the Burden of HPV-associated Cancers

By

Although HPV vaccination is expected to decrease the cancer burden from HPV across all racial and ethnic groups, some disparities are expected to persist and widen if their causes are not addressed, including lack of access to screening, timely diagnoses, and treatment.

Staging by Lymph Node Categories Shown to Better Predict Survival in Patients With Oropharyngeal Cancer

By

The current staging system for oropharyngeal cancer does not adequately differentiate HPV-positive from HPV-negative OPC. These researchers suggest regional OPC lymph node (N) categories and nasopharyngeal N categories might be more useful in staging HPV-positive OPC.

Imaging, Physical Examination Find Most Recurrences of HPV-positive Oropharyngeal Cancer

By

Posttreatment imaging at 3 months and physical examinations during the 6 months following treatment can detect most recurrences in patients treated with definitive radiation therapy for HPV-associated oropharyngeal cancer.

Serum HPV Antibody Levels May Be a Biomarker for Recurrent HPV-associated Oropharyngeal Cancer

By

Among patients treated for oropharyngeal cancers linked to human papillomavirus (HPV) infection, at least 1 HPV-infection antibody could help identify those patients at risk for a recurrence of the cancer.

HPV Oropharyngeal Cancer Prevalence varies by Geographic Region

HPV Oropharyngeal Cancer Prevalence varies by Geographic Region

HPV-positive oropharyngeal cancer prevalence varies between Western Europe and Eastern Europe, according to study data.

Depressed Head and Neck Cancer Patients Have Lower Survival and Higher Recurrence Risk

By

Depression is a significant predictor of 5-year survival and recurrence in patients with head and neck cancer. These findings represent one of the largest studies to report on the impact of depression on cancer survival.

HPV16 DNA in oral rinse found to be prognostic of oropharyngeal cancer recurrence

By

Oropharyngeal cancer patients with detectable traces of human papillomavirus type 16 (HPV16) in their saliva after cancer treatment are at an increased risk for recurrence.

HPV16 detection after oropharyngeal cancer treatment may increase risk for recurrence

HPV16 detection after oropharyngeal cancer treatment may increase risk for recurrence

Patients with oropharyngeal cancer who were found to have detectable traces of human papillomavirus type 16 (HPV16) in their saliva.

Blood antibodies may predict survival of HPV-positive oropharyngeal cancer

By

The presence of certain human papillomavirus (HPV)-16 antibodies in the blood is associated with improved survival rates for patients with HPV-related oropharyngeal carcinoma.

Persistent HPV16 in Oral Rinses Signals Poor Prognosis for HPV-Positive Oropharyngeal Carcinoma

Persistent HPV16 in Oral Rinses Signals Poor Prognosis for HPV-Positive Oropharyngeal Carcinoma

By

Detection of human papillomavirus (HPV)16 DNA in oral rinses following treatment for HPV-positive oropharyngeal carcinoma could be a potential tool for long-term tumor surveillance, a study concluded at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.

HPV vaccine may be cost-effective strategy for preventing oropharyngeal cancer in males

HPV vaccine may be cost-effective strategy for preventing oropharyngeal cancer in males

Human papillomavirus (HPV) vaccine may be a cost-effective approach for preventing squamous cell oropharyngeal cancer.

Challenges exist in treating HPV oropharyngeal cancer patients

Challenges exist in treating HPV oropharyngeal cancer patients

Mixed views have been expressed in relation to explaining the causal role of HPV in oropharyngeal cancer.

Patients with HPV-positive oropharyngeal cancer may not require post-radiation surgery

Patients with HPV-positive oropharyngeal cancer may not require post-radiation surgery

Human papillomavirus (HPV)-positive oropharyngeal cancer may not require neck surgery after receiving radiation therapy and chemo.

Blood and saliva tests help predict return of human papillomavirus (HPV)-linked oral cancers

By

Physicians have developed blood and saliva tests that help accurately predict recurrences of HPV-linked oral cancers in a substantial number of patients. The tests screen for DNA fragments of the HPV shed from cancer cells lingering in the mouth or other parts of the body.

HPV-positive status tied to oropharyngeal cancer survival

HPV-positive status tied to oropharyngeal cancer survival

Human papillomavirus (HPV) positivity is associated with improved survival after disease progression, according to a study.

Reduced-dose radiation safe for certain patients with low-risk HPV-positive oropharyngeal cancer

Reduced-dose radiation safe for certain patients with low-risk HPV-positive oropharyngeal cancer

By

Reduced-dose intensity-modulated radiotherapy after complete clinical responses to induction chemotherapy for operable stage III/IVA, human papillomavirus (HPV)-positive head and neck cancer appears to be safe and might improve patients' quality of life.

Gabapentin benefits oropharyngeal cancer patients

By By

ANAHEIM, CALIFORNIA—Among oropharyngeal patients receiving radiotherapy, gabapentin improved pain management and reduced weight loss, which potentially prevents the need for placement of a gastrostomy tube, according to a study presented at the Oncology Nursing Society (ONS) 39th Annual Congress.

Before HPV vaccine, most oropharyngeal cancers HPV positive

Before HPV vaccine, most oropharyngeal cancers HPV positive

Most oropharyngeal cancers in the United States diagnosed between 1995 and 2005 were positive for human papillomavirus (HPV), according to a study.

Oropharyngeal cancer symptoms vary by HPV status

Oropharyngeal cancer symptoms vary by HPV status

Initial symptom presentation seems to differ for human papillomavirus (HPV)-positive versus HPV-negative patients with oropharyngeal squamous cell carcinoma, according to a study.

Patients with oropharyngeal cancer report quality of voice and speech affected posttreatment

By

Oropharyngeal cancer patients treated with combined chemotherapy and radiation therapy reported a decrease in their voice and speech quality for up to a year after the completion of treatment.

Recurrent mouth and throat cancers less deadly when caused by HPV

By

People with late-stage cancer at the back of the mouth or throat that recurs after chemotherapy and radiation treatment are twice as likely to be alive 2 years later if their cancer is caused by the human papillomavirus.

OPSCC incidence up from 1973 to 2009

OPSCC incidence up from 1973 to 2009

Increased incidence of of oropharyngeal squamous cell carcinoma (OPSCC) among patients younger than 45 years seen, and steady increase in proportion of grade III/IV tumors.

HPV linked to growing number of young adults with oropharyngeal cancer

By

The human papillomavirus (HPV) may be to blame for the alarming increase of young adults with oropharyngeal cancer.

ASTRO: Oropharyngeal cancer on the rise in younger patients

ASTRO: Oropharyngeal cancer on the rise in younger patients

Survival highest for patients with both surgery, radiation, but lowest in African-Americans.

Single men and smokers face higher risk for oral HPV infection

By

Smokers and single men are more likely to acquire cancer-causing oral human papillomavirus (HPV), according to new results from the HPV Infection in Men (HIM) Study.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs